Eggelmeijer F, Papapoulos S E, van Paassen H C, Dijkmans B A, Breedveld F C
Department of Rheumatology, Leiden, The Netherlands.
J Rheumatol. 1994 Nov;21(11):2016-20.
To assess the effects of 3-amino-1-hydroxypropylidine-1,1-bisphosphonate (pamidronate) in rheumatoid arthritis (RA).
Thirty patients with active RA were randomly allocated to receive a single intravenous infusion of placebo, 20 mg pamidronate, or 40 mg pamidronate.
Pamidronate treatment resulted in a rapid and sustained reduction in urinary calcium and hydroxyproline excretions. A sustained reduction in serum corrected calcium was only noted in the group treated with 40 mg pamidronate. In both groups treated with pamidronate a temporary increase in serum parathyroid hormone was noted. Compared to the placebo group clinical variables of disease activity improved significantly in both groups treated with aminohydroxypropylidine bisphosphonate. The erythrocyte sedimentation rate and serum C-reactive protein levels improved significantly in patients treated with 40 mg pamidronate. No serious side effects were documented.
A single infusion of pamidronate in patients with RA is safe, suppresses bone resorption, and reduces disease activity. It is suggested that the effect on disease activity is dose dependent.
评估3-氨基-1-羟丙基-1,1-双膦酸盐（帕米膦酸盐）对类风湿关节炎（RA）的疗效。
30例活动期RA患者被随机分配接受单次静脉输注安慰剂、20mg帕米膦酸盐或40mg帕米膦酸盐。
帕米膦酸盐治疗导致尿钙和羟脯氨酸排泄迅速且持续减少。仅在接受40mg帕米膦酸盐治疗的组中观察到血清校正钙持续降低。在接受帕米膦酸盐治疗的两组中均观察到血清甲状旁腺激素暂时升高。与安慰剂组相比，氨基羟丙基双膦酸盐治疗的两组疾病活动的临床变量均有显著改善。接受40mg帕米膦酸盐治疗的患者红细胞沉降率和血清C反应蛋白水平显著改善。未记录到严重副作用。
对RA患者单次输注帕米膦酸盐是安全的，可抑制骨吸收并降低疾病活动度。提示对疾病活动度的影响呈剂量依赖性。
